About harmony biosciences holdings inc - HRMY
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.
HRMY At a Glance
Harmony Biosciences Holdings, Inc.
630 West Germantown Pike
Plymouth Meeting, Pennsylvania 19462
| Phone | 1-484-539-9800 | Revenue | 868.45M | |
| Industry | Pharmaceuticals: Major | Net Income | 158.69M | |
| Sector | Health Technology | 2025 Sales Growth | 21.507% | |
| Fiscal Year-end | 12 / 2026 | Employees | 293 | |
| View SEC Filings |
HRMY Valuation
| P/E Current | 13.691 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 13.806 |
| Price to Sales Ratio | 2.523 |
| Price to Book Ratio | 2.482 |
| Price to Cash Flow Ratio | 6.29 |
| Enterprise Value to EBITDA | 7.059 |
| Enterprise Value to Sales | 1.90 |
| Total Debt to Enterprise Value | 0.142 |
HRMY Efficiency
| Revenue/Employee | 2,964,003.413 |
| Income Per Employee | 541,593.857 |
| Receivables Turnover | 8.973 |
| Total Asset Turnover | 0.765 |
HRMY Liquidity
| Current Ratio | 3.597 |
| Quick Ratio | 3.576 |
| Cash Ratio | 3.075 |
HRMY Profitability
| Gross Margin | 74.416 |
| Operating Margin | 24.005 |
| Pretax Margin | 24.764 |
| Net Margin | 18.272 |
| Return on Assets | 13.976 |
| Return on Equity | 20.752 |
| Return on Total Capital | 14.357 |
| Return on Invested Capital | 17.236 |
HRMY Capital Structure
| Total Debt to Total Equity | 27.012 |
| Total Debt to Total Capital | 21.268 |
| Total Debt to Total Assets | 18.485 |
| Long-Term Debt to Equity | 17.027 |
| Long-Term Debt to Total Capital | 13.406 |